Abstract

Economists, a biomedical researcher and a business executive have formulated three contrasting proposals to address the shortfall in antibiotic R&D. Their proposals, which emphasize advance purchase contracts, not-for-profit research, and tax incentives, respectively, share some features with provisions in bills pending before the US Congress that could potentially reshape the R&D landscape for this essential class of drugs.

Author affiliations

1. Carl Nathan is in the Department of Microbiology and Immunology, Weill Medical College of Cornell University, 1300 York Avenue, New York, New York 10021, USA, and the Graduate Programs in Immunology and Microbial Pathogenesis and Molecular Biology, Weill Graduate School of Medical Sciences of Cornell University, New York, New York, USA
2. Frederick M. Goldberg is at Saltchuk Resources, Inc., 1111 Fairview Avenue North, Seattle, Washington 98109, USA.

Correspondence to: Carl Nathan¹ Email: cnathan@med.cornell.edu

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.